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Having reviewed the recent literature on the anti-estrogen 
drug tamoxifen, I am concerned about the recently initiated 
National Cancer Institute (NCI) clinical trial to determine the 
worth of tamoxifen for preventing breast cancer in healthy 
women, the NSABP (National Surgical Adjuvant Breast and 
Bowel Project) Protocol P-1. This $60-million trial will enroll 
16,000 women: half placebo controls, and the other halftamoxifen 
subjects. The latter group includes all women over the age of 60, 
and women between the ages of35 to 59 whose minimum 5-year 
risk is at least that of a woman >60 (calculated by a composite 
mathematic model weighing family history, age of menarche, 
number of relatives with breast cancer and other factors). 
While there does not appear to be a problem with enrolling 
women with the highest risk of developing breast cancer in such 
a trial (those with the diagnosis of lobular carcinoma in situ or 
those who have both a mother and a sister with breast cancer), 
the current study design of subjecting all60-year-olds as well as 
younger, lower-risk women to prolonged tamoxifen exposure 
may not be warranted, based on several recent studies that have 
been released since the protocol was completed. This may be 
especially true for Hawaiian and oriental populations forreasons 
that will be explained. 
Tamoxifen was chosen for this trial because it has been 
shown in several large studies 1-4 to reduce the recurrence of 
contralateral breast cancers in women who have had estrogen 
receptor-positive (hormone sensitive) primary breast cancer. 
These studies were all short-term, actuarial trials in nature, 
looking only at survival rates and disease-free intervals and did 
not routinely include biopsy or autopsy examinations of study 
and control groups. This may have led to an underestimation of 
new, non-metastatic malignancies that were either missed or 
mistaken for metastatic breast cancer. 
This is an important consideration because of the animal 
and human studies that have demonstrated tamoxifen to be a 
cancer promoter in uterine, hepatic and estrogen receptor-
negative breast cancers. In the Swedish study3, there was an 
excess of nonfatal endometrial cancers in the test group (1.4% 
tamoxifen group vs 0.2% control group). There are several case 
reports of uterine cancer in women taking tamoxifen5-7• When 
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combined with the new evidence that tamoxifen is a teratogen 
in the developing female genital tract, with strong similarities 
to diethylstilbesteroP, these studies predict a danger to both 
postmenopausal and premenopausal women that is not 
sufficiently addressed in the current NSABP P-1 Protocol and 
its informed consent form (1124/92 version). 
Postmenopausal women who have not had hysterectomies 
are required by the protocol to have pelvic examinations at 
initiation of the study and every 12 months thereafter. The study 
protocol states that in the case of menstrual irregularities which 
persist in the face of normal pelvic exams, the patient should 
undergo further testing such as hysteroscopy or dilatation and 
curettage (D&C). These expensive procedures, as are all office 
exams, lab tests and procedures, are charged to the patient, 
which might prove to be a deterrent to careful follow up for 
uninsured or indigent patients. The possibility that endometrial 
carcinoma may develop in patients without obvious menstrual 
irregularities until late in the course of their cancer is not 
addressed. Untreated uterine carcinoma is a major cause of 
morbidity in women who have it. 
Premenopausal women in the study are advised on the one 
hand notto become pregnant, as tamoxifen is a human teratogen, 
and on the other hand, they are told not to use birth control pills 
because estrogens will interfere with the action of tamoxifen. It 
is well-known that barrier methods of birth control have a high 
failure rate 9, as does the rhythm method. The consent form also 
discourages the use of IUDs because they promote menstrual 
irregularities. These factors, when coupled with the clomiphene-
like propensity oftamoxifen to increase fertility, may increase 
the likelihood that premenopausal women may indeed find 
themselves pregnant while taking tamoxifen. At this point, the 
protocol and the informed consent form also fail to provide 
funding or moral and legal support for the abortion which would 
presumably be indicated. 
Tamoxifen is a known liver carcinogen in rats. At doses of 
35 mg/kg/day, it caused hepatocellular carcinomas at between 
31 and 37 weeks of use 10• Other studies have shown 
carcinogenicity at lower doses. At an average of 40 kg to 60 kg 
weight for an average 60-year-old woman in the study, the 
margin of safety is somewhat less than a factor of 100, which is 
the accepted standard of protection for humans in the face of a 
known carcinogen. The half-life of tamoxifen is longer in 
humans than in rats, which may further compromise this safety 
factor. The tumors in rats are highly malignant, perhaps explained 
by the finding of the induction of covalent DNA adducts with 
tamoxifen, with mutations occurring within a few days of 
starting the drug 11 • 
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The Swedish tamoxifen triaP found 2liver carcinomas in its 
study population, which was several-fold higher than the average 
incidence of this tumor. As mentioned before, other studies have 
either not looked for it or may have mistaken it for metastatic 
breast cancer. Very few healthy women have taken tamoxifen for 
more than 5 years, and therefore very little adequate human data 
have been obtained to conclude that tamoxifen is or is not 
hepatotoxic in humans 12• The NSABP P-1 protocol does not call 
for specific liver function testing but mentions only "chemistry 
tests" to be done every 6 months. 
In other work published this year and not referenced by the 
study protocol is a work by Zimnisky et al in which tamoxifen 
was found to promote growth of dimethylbenzanthracene-
induced, hormone-independent tumors in the rat mammary 
gland. While growth of hormone-dependent tumors was, as 
expected, decreased significantly in the tamoxifen group, 
hormone-independent mammary tumors developed during 
tamoxifen administration and displayed ", .. extremely rapid 
growth"13 • These tumors grew 3 times faster than similar hormone-
independent tumors in control animals, as well as significantly 
faster than hormone-dependent tumors. In the discussion of this 
paper, the authors point out that tamoxifen has been shown in 
other studies merely to delay the onset of hormone-sensitive 
tumors. 
Fen timan, of the Royal Marsden Hospital in London, points 
out that tumors in younger women are likely to be receptor-
negative, and goes on to say, "If, however, the malignant 
phenotype ie receptor-positive is inhibited for say 2 to 5 years, 
with subsequent emergence of a more aggressive hormone-
independent variant, the prognosis might be worse if no tamoxifen 
had been given"14• 
In Hawaii, this consideration of induction of estrogen 
receptor-negative malignancy carries greater significance because 
of the greater prevalence of estrogen receptor-negative disease 
that our Japanese population exhibits15 • 
Other considerations involve the significant incidence of 
ocular toxicity and thrombophlebitis in women receiving 
tamoxifen. In a prospective study of 63 women receiving low 
dose (20 mg/d), long-term tamoxifen, 6.3% of the subjects 
developed retinopathy and/or keratopathy from between 10 to 35 
months of initiation of therapy16• Unfortunately, the protocol and 
the informed consent do not mention the probability of ocular 
disease development at low doses of tamoxifen to either the 
investigators or to the prospective study enrollees, and does not 
recommend or provide foreitherroutine ophthalmological exams 
or slit-lamps, both of which should be mandated based on this 
and other information. 
In the NSABP B-14 Trial, 3 of 1,414 women in the control 
group and 18 of the 1,403 women in the tamoxifen group 
developed deep venous thromboses or embolism. Two deaths 
occurred from pulmonary embolus 1• If this incidence is 
extrapolated to 8,000 healthy women, some of whom have an 
increased statistical risk of developing breast cancer, we can 
expect approximately 80 of them to develop deep venous 
thrombosis or an embolic event, and around 9 or 10 of them to die 
of massive pulmonary embolus. 
In addition, there is ample evidence that tamoxifen causes 
significant side effects in those who take it over the long term. In 
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a recent study of 140 patients receiving adjuvant tamoxifen 
therapy, 17% had moderate to severe vasomotor symptoms and 
gynecologic symptoms in 4% 17• In their conclusions, the authors 
state, " ... this study suggests that in a population of postmenopausal 
women with a history of axillary node negative breast cancer, 
almost half of the tamoxifen-treated women will report moderate 
or greater levels of symptoms." Premenopausal women may 
have an even higher incidence of side effects. How this will 
affect their compliance with a long-term, preventive tamoxifen 
trial remains to be seen. 
In conclusion, while I do not have a problem with the use of 
tamoxifen for the prevention ofbreast cancer in the older, higher-
risk patients, there is an obvious ethical problem when we submit 
healthy women of child-bearing age, who have a nil to slightly 
increased risk of breast cancer, to a known carcinogen which, in 
addition to increasing their fertility, is also a demonstrated 
teratogen. This is especially problematic when they are forbidden 
the most effective forms of birth control and are not advised to 
have routine endometrial exams. These risks are compounded by 
the possibility of an increased incidence of hepatocellular 
carcinoma and estrogen receptor-negative breast carcinoma, as 
well as a significant probability of developing ocular toxicity or 
thrombophlebitis. 
Clinicians who are advising patients interested in enrolling 
in this study would do well to aquaint themselves with the 
availiable literature on the toxicity of tamoxifen, some of the 
most impressive of which has been published since the latest 
protocol was completed. In this way they may persuade both 
themselves and their patients that prudence in entering this trial 
is well-warranted. 
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